Stratec SE buy melinda
Start price
17.11.17
/
50%
€64.00
Target price
20.11.17
€65.50
Performance (%)
2.73%
End price
20.11.17
€65.75
Summary
This prediction ended on 20.11.17 with a price of €65.75. The BUY prediction by melinda finished with a performance of 2.73%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Stratec SE | -3.704% | -3.704% | -35.942% | -73.277% |
| iShares Core DAX® | 0.734% | -0.964% | 17.910% | 65.510% |
| iShares Nasdaq 100 | -2.686% | -2.409% | 4.267% | 95.368% |
| iShares Nikkei 225® | -2.261% | -4.038% | 10.420% | 42.232% |
| iShares S&P 500 | -1.346% | -1.510% | 1.615% | 59.132% |
According to melinda what are the pros and cons of Stratec SE for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Stratec Biomedical AG diskutieren
SecteurEquipement und moderne medizinische Technologie Präsentation Agenda 28/11
STRATEC Biomedical AG, die in der Konstruktion und Herstellung von automatisierten Analysensystemen auf dem Gebiet der klinischen Diagnose und biotechnology.It betreibt durch die folgenden Segmente: Instrumentation, Diatron, Verbrauchsmaterial und alle other.The Instrumentation Segment Bezieht sich auf das Design und
(Zielkurs erreicht)
Stopped prediction by melinda for Stratec SE
Stratec SE
Start price
Target price
Perf. (%)
€122.40
30.12.20
30.12.20
€128.00
30.12.21
30.12.21
12.75%
31.12.21
31.12.21
Could be worthwhile Investment >10% per year


